Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH3G10 in STEMI undergoing PCI (phase IIa pilot)
2018-003676-12Phase 2Completed
- Sponsor
- Athera Biotechnologies AB
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing ATH3G10 with Placebo (2 arms). Primary endpoint: Left Ventricular End-Diastolic Volume index (LV EDVi) change. Started Oct 2018; status: completed.
02
Drugs
ABR-001
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2018-003676-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003676-12.